AOD-9604 (Tyr-hGH177-191) has emerged as a critical peptide in metabolic research, specifically for its potential to accelerate. AOD-9604 is a modified form of amino acids 177-191 of Human Growth Hormone. Foundational research by scientists like Ng FM and Summers R established the safety and efficacy profile of this peptide. It works by mimicking the lipolysis (fat breakdown) without the adverse glycemic effects of full-length growth hormone. For principal investigators and laboratory professionals, establishing a precise AOD 9604 protocol is the first step toward reproducible data.
While many studies focus on its chemical structure, there is a lack of standardized data regarding the best time to take AOD 9604 (administer to subjects), optimal cycle length, and reconstitution methods. This guide serves as a comprehensive manual for Research Use Only (RUO) applications, consolidating data from seminal studies to provide a clear AOD 9604 peptide dosage framework.
Disclaimer: This content is for educational purposes regarding laboratory chemical handling. AOD-9604 is not FDA-approved for human consumption. All “dosage” references apply to preclinical animal models (murine/rodent).
What is AOD-9604? (Mechanism & Chemistry)
AOD-9604 is a modified, cyclic fragment of the Human Growth Hormone C-terminus (amino acids 177-191). Unlike the linear hGH Fragment 176-191, AOD-9604 features a disulfide bridge between two cysteine residues. This cyclization is crucial: it renders the peptide significantly more stable against proteolytic enzymes in plasma, enhancing its bioavailability. Lipolysis (Fat breakdown). The primary function of AOD-9604 is to regulate fat metabolism by stimulating lipolysis specifically in adipose tissue, without affecting blood sugar levels.”
- Anti-lipogenic (Fat prevention)
- Adipose tissue (Fat cells)
- Beta-3 adrenergic receptorsPituitary gland
- HGH Fragment 176-191
IGF-1
How It Works: The Lipolytic Pathway
The primary AOD-9604 mechanism involves the upregulation of beta-3 adrenergic receptors (β3-AR) in white adipose tissue.
Fat Release: It stimulates the release of glycerol and fatty acids from adipocytes.
Inhibition: It prevents lipogenesis (the storage of new fat) by inhibiting the transformation of pre-adipocytes into mature fat cells.
Safety: Crucially, it does not bind to the hGH receptor responsible for IGF-1 (Insulin-like Growth Factor 1) secretion, meaning it avoids the “growth” side effects (acromegaly, insulin resistance) associated with HGH.
Research Applications & Potential Benefits. “While understanding the correct dosage is critical, it is equally important to define the expected outcomes. AOD-9604 is widely researched because it offers multiple benefits, primarily focusing on fat reduction without affecting blood sugar. In clinical studies, this peptide has shown significant potential in helping subjects achieve specific weight loss goals. Furthermore, by targeting fat metabolism directly, it plays a key role in improving overall body composition.”
AOD 9604 Dosage for Beginners (Preclinical Research)
When designing a study, determining the AOD 9604 dosage for beginners (initial pilot studies) can be challenging due to conflicting literature. The effective therapeutic window in rodent models is surprisingly wide, but precision is key for statistical significance.
Standard Dosage Guidelines
For most metabolic studies involving C57BL/6J mice (diet-induced obesity models) or Zucker fatty rats, the consensus research dosage falls into the following ranges:
- Low Dose (Sensitivity Testing): 250 mcg/kg/day
- Standard Therapeutic Dose: 300 mcg/kg – 500 mcg/kg/day
- High Dose (Toxicology Limits): Up to 1000 mcg/kg/day (No adverse effects observed in acute toxicity studies).
For researchers translating this to “human equivalent” calculations for theoretical papers, the standard AOD 9604 dosage per day often cited in clinical trials (like the classic Heffernan studies) is 300 mcg to 1 mg total daily dose applied to the subject.
AOD 9604 Dosage Chart
To simplify your laboratory protocols, use this AOD 9604 dosage chart. This reference table helps technicians quickly calculate the required volume based on a standard reconstitution concentration.
| Subject Weight (Model) | Target Dosage (Daily) | Concentration (2mg/ml) | Volume to Administer |
| Mouse (25g) | 300 mcg/kg | 2000 mcg/ml | ~0.00375 ml (3.75 µL) |
| Rat (300g) | 500 mcg/kg | 2000 mcg/ml | 0.075 ml (7.5 Units) |
| Rat (500g) | 500 mcg/kg | 2000 mcg/ml | 0.125 ml (12.5 Units) |
| *Large Subject (75kg) | 300 mcg total | 2000 mcg/ml | 0.15 ml (15 Units) |
| *Large Subject (75kg) | 500 mcg total | 2000 mcg/ml | 0.25 ml (25 Units) |
Note: Large subject data refers to theoretical scaling or non-human primate models. Always verify calculations with your specific vial concentration.
AOD 9604 Protocol & Cycle Length
A successful experiment requires more than just a daily dose; it requires a structured AOD 9604 protocol.
AOD-9604 Dosage Guidelines for Research.”AOD-9604 In-Vitro In-Vivo Dosing Guide.
How long is a typical AOD 9604 cycle?
In metabolic research, physiological changes are rarely immediate.
- Acute Lipolysis: Short-term spikes in glycerol release can be measured within 2-4 hours of administration.
- Chronic Weight Loss: Significant reduction in adipose tissue mass typically requires an AOD 9604 cycle length of 12 to 24 weeks.
- Short Cycles: Cycles shorter than 4 weeks often fail to show statistically significant weight reduction in obese phenotypes, although metabolic markers (like glucose tolerance) may improve sooner.
Best Time to Take AOD 9604 (Administration Timing)
One of the most common queries in the data is: “When to take AOD 9604, morning or night?”
Research indicates that fasted administration is superior.
- Morning Administration: The best time to take AOD 9604 is immediately upon the start of the “active” phase (morning for humans/diurnal animals), in a completely fasted state. The presence of insulin spikes (from food) can blunt the lipolytic signaling cascade.
- Taking AOD 9604 at Night: While feasible, evening administration must occur several hours post-feeding. If the subject has elevated blood glucose/insulin, the peptide’s efficacy is reduced.
- Split Dosing: For higher total dosages (e.g., 1000 mcg/day), some protocols split the dose: 50% in the AM (fasted) and 50% pre-sleep (fasted).
AOD 9604 Reconstitution Instructions
Correct peptide handling is the most overlooked variable in failed experiments. Below are the standard AOD 9604 mixing instructions.
Subcutaneous injection
- Bacteriostatic water
- Reconstitution
- Vial
- Micrograms (mcg)
- Bioavailability
Step-by-Step Mixing Guide
Materials Needed:
- Lyophilized AOD-9604 Vial (typically 2mg or 5mg).
- Bacteriostatic Water (Bac Water) or Sterile Saline.
- Alcohol swabs.
Procedure:
- Clean: Swab the rubber stopper of the peptide vial and the diluent vial.
- Withdraw: Pull the desired amount of Bacteriostatic Water into the syringe (e.g., 2ml is standard for a 5mg vial to create a manageable concentration).
- Inject: Slowly inject the water into the AOD-9604 vial. Do not spray directly onto the powder. Aim for the glass wall to let the water trickle down.
- Dissolve: The solution may look cloudy initially. Do not shake. Gently swirl the vial in a circular motion until the powder is fully dissolved and the solution is clear.
- Rest: Let the vial sit in the refrigerator for 10-15 minutes before first use to ensure complete equilibration.
AOD 9604 Mixing Instructions (Common Ratios)
- 2mg Vial + 1ml Water: = 2000mcg per ml (20mcg per unit on a standard insulin syringe).
- 5 mg Vial + 2 ml Water: = 2500 mcg per ml (25 mcg per unit).
- 5 mg Vial + 2.5 ml Water: = 2000 mcg per ml (Easier math: 20 mcg per unit).
AOD-9604 Research Dosage Chart (RUO): Guide for In-Vitro anti-lipogenic concentration and In-Vivo mg/kg dosing for fat oxidation in rodents.
AOD 9604 Dosage for Fat Loss vs. Repair
Does the dosage change based on the research goal? Yes. The AOD 9604 dosage for fat loss (metabolic study) differs from tissue repair protocols.
Metabolic (Fat Loss) Protocols
- Dose: 300 mcg – 500 mcg daily.
- Frequency: Daily, strictly fasted.
- Focus: Visceral fat reduction, prevention of non-alcoholic fatty liver disease (NAFLD).
Cartilage & Repair Protocols
- Dose: 250 mcg daily or localized intra-articular injections (in rabbit/equine models).
- Mechanism: Synergistic effect with Hyaluronic Acid (HA) to promote chondrocyte regeneration.
- Timing: Less dependent on fasting states compared to fat loss protocols.
Osteoarthritis. - Cartilage regeneration
Beyond fat loss, emerging studies suggest that AOD-9604 may support cartilage health and could be beneficial for joint repair in conditions like osteoarthritis.”
AOD 9604 vs. Semaglutide & Stacks
Modern research rarely studies peptides in isolation. A trending area of inquiry is the AOD 9604 stack.
- AOD-9604 + BPC-157: Often researched for systemic healing (gut + metabolic).
- AOD-9604 + CJC-1295: Studied for maximizing growth hormone pulses without the hunger associated with GHRP-6.
Does AOD-9604 work for women?
Yes. AOD 9604 dosage for women (female animal models) is typically identical to male models on a per-kilogram basis. However, female models often show higher resistance to diet-induced obesity, so statistically significant results may require longer AOD 9604 cycle lengths.
Frequently Asked Questions
How much AOD 9604 should I take daily?
In a research setting, the standard starting point is 300 mcg per day. If no response is observed after 4 weeks, titrate up to 500 mcg per day. Doses beyond 1000 mcg yield diminishing returns.
Is there an FDA Warning for AOD-9604?
Yes. The FDA has issued warnings that AOD-9604 is not approved for compounding in humans and is not on the “Category 1” bulk substance list. It is legal for Research Use Only (RUO) and veterinary applications in some jurisdictions, but it cannot be sold as a dietary supplement or human drug.
How to use the AOD 9604 peptide accurately?
Always use a U-100 insulin syringe for precision. If your concentration is 2000mcg/ml, drawing to the “15” tick mark equals 300mcg.
Can you mix AOD 9604 with other peptides?
Yes. AOD-9604 is chemically stable and can be mixed in the same syringe with other neutral-pH peptides like BPC-157 to reduce the number of injections required for the subject.
Conclusion
AOD-9604 remains one of the most promising peptides in the metabolic researcher’s toolkit. By adhering to a strict AOD 9604 protocol—specifically ensuring fasted administration and correct reconstitution—investigators can unlock its potent lipolytic properties.
Whether investigating AOD 9604 dosage for fat loss in obese mice or exploring its regenerative capacity in osteoarthritic tissue, consistency is the variable that matters most. Utilize the dosage chart and reconstitution instructions provided above to standardize your laboratory’s approach to this unique peptide. For individuals struggling with obesity, incorporating this peptide into a structured protocol can effectively help achieve sustainable weight loss goals.”
